<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4391"><DrugName>SDZ-NVI-085</DrugName><DrugSynonyms><Name><Value>SDZ-NVI-085</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>104195-17-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="23137">Novartis AG</Company><Company id="24481">Sandoz Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4391" type="Drug"><TargetEntity id="116463" type="siDrug">SDZ-NVI-085</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24481" type="Company"><TargetEntity id="4297283322" type="organizationId">Sandoz Pharmaceuticals AG</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="15" type="ciIndication"><TargetEntity id="10001949" type="MEDDRA"></TargetEntity><TargetEntity id="D000647" type="MeSH"></TargetEntity><TargetEntity id="-1501831747" type="omicsDisease"></TargetEntity><TargetEntity id="107" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="304" type="ciIndication"><TargetEntity id="G47" type="ICD10"></TargetEntity><TargetEntity id="10040984" type="MEDDRA"></TargetEntity><TargetEntity id="D012893" type="MeSH"></TargetEntity><TargetEntity id="-901040789" type="omicsDisease"></TargetEntity><TargetEntity id="75" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="353" type="ciIndication"><TargetEntity id="10057668" type="MEDDRA"></TargetEntity><TargetEntity id="D019965" type="MeSH"></TargetEntity><TargetEntity id="-1363718134" type="omicsDisease"></TargetEntity><TargetEntity id="98" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="90" type="ciIndication"><TargetEntity id="10012267" type="MEDDRA"></TargetEntity><TargetEntity id="D003704" type="MeSH"></TargetEntity><TargetEntity id="-1720562635" type="omicsDisease"></TargetEntity><TargetEntity id="100" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6908" type="Action"><TargetEntity id="51" type="Mechanism">alpha1A-Adrenoceptor Agonists</TargetEntity><TargetEntity id="2205" type="Mechanism">Alpha1L-Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00106" type="ciTarget"><TargetEntity id="15146462831483" type="siTarget">Alpha-1A adrenergic receptor</TargetEntity><TargetEntity id="-2013430205" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication><Indication id="15">Amnesia</Indication><Indication id="304">Sleep disorder</Indication><Indication id="353">Cognitive disorder</Indication><Indication id="90">Dementia</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="6908">Alpha 1A adrenoceptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="284">Nootropic agent</Action><Action id="2941">Antidepressant</Action><Action id="2944">Hypnotic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N5B</Code><Name>HYPNOTICS/SEDATIVES</Name></Ephmra><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T05:45:44.000Z</LastModificationDate><ChangeDateLast>2005-12-29T13:42:47.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; (formerly Sandoz) has discontinued development of SDZ-NVI-085 [&lt;ulink linkID="347827" linkType="reference"&gt;347827&lt;/ulink&gt;], a selective, centrally acting, alpha 1 adrenoceptor agonist [&lt;ulink linkID="3709" linkType="reference"&gt;3709&lt;/ulink&gt;] with specificity for the alpha 1a noradrenergic receptor subtype [&lt;ulink linkID="3706" linkType="reference"&gt;3706&lt;/ulink&gt;], [&lt;ulink linkID="3707" linkType="reference"&gt;3707&lt;/ulink&gt;], as a potential treatment for various cognitive disorders. It had reached phase I clinical trials for the treatment of various cognitive disorders including narcolepsy, dementia and amnesia [&lt;ulink linkID="3709" linkType="reference"&gt;3709&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Studies in healthy volunteers found no clinically relevant effects on blood pressure or heart rate [&lt;ulink linkID="3709" linkType="reference"&gt;3709&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;SDZ-NVI-085 is lipophilic and has good brain penetration with minimal cardiovascular effect in animals [&lt;ulink linkID="3709" linkType="reference"&gt;3709&lt;/ulink&gt;]. The compound facilitates the maintenance of vigilance [&lt;ulink linkID="3709" linkType="reference"&gt;3709&lt;/ulink&gt;] and reverses canine cataplexy [&lt;ulink linkID="3708" linkType="reference"&gt;3708&lt;/ulink&gt;], a sleep disorder similar to human narcolepsy, characterized by bouts of sleep attacks.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Alex A Cordi, PhD, Institut de Recherches &lt;ulink linkType="Company" linkID="19863"&gt;Servier&lt;/ulink&gt;, Suresnes, France&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;25 July 1996&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR &lt;/subtitle&gt;Several 2-amino tetralines are known to interact with various bioamine receptors and the selectivity of these interactions is very sensitive to the substitution pattern on the phenyl ring and on the basic nitrogen atom [&lt;ulink linkType="reference" linkID="191016"&gt;191016&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; was designed as a rigidified form of SKF-89748A (&lt;ulink linkType="Company" linkID="19962"&gt;SmithKline Beecham&lt;/ulink&gt;), a selective alpha 1 adrenoceptor agonist and was synthesized in 10 steps and in 2.5% overall yield, starting from a noncommercial intermediate [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Limited SAR have been described [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;]. Nitrogen substitution, replacement of the oxygen by a methylene in the oxazine, cis- or trans- ring fusion and substitution of the thiomethyl moiety on the benzo group by chloro, nitro and thioethyl residues. Among the 15 compounds described, &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; was the only one fulfilling all the selection criteria.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In isolated organ experiments, &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; has shown alpha 1a adrenoceptor partial agonist properties in rabbit ear artery, rat vas deferens and rat kidneys, whilst being much less active in rat aorta and guinea pig spleen [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="3706"&gt;3706&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="3707"&gt;3707&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="162763"&gt;162763&lt;/ulink&gt;]. These activities were correlated with its binding affinities to native (rat liver, rat cortex, rabbit liver) [&lt;ulink linkType="reference" linkID="162763"&gt;162763&lt;/ulink&gt;], and cloned (COS cell expressed) [&lt;ulink linkType="reference" linkID="162766"&gt;162766&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="162775"&gt;162775&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="162778"&gt;162778&lt;/ulink&gt;] alpha 1 adrenoceptor subtypes. In rat cortex slices, &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; stimulates the breakdown of phosphatidyl inositol, with an efficacy of 45% and a pD(2) of 6.1, compared to phenylephrine's 100% efficacy and pD(2) value of 5.1. In addition, the compound behaves as a 5-HT2 receptor antagonist in the rat aorta [&lt;ulink linkType="reference" linkID="201039"&gt;201039&lt;/ulink&gt;] and binds with high affinity to the 5-HT1d (pK(D) = 8.1) and 5-HT1a (pK(D) = 7.4) receptors [&lt;ulink linkType="reference" linkID="196222"&gt;196222&lt;/ulink&gt;], where it acts as an agonist.&lt;/para&gt;&lt;para&gt;In the pithed rat, &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; induces hypertensive responses (pD(2) = 6.74) which are antagonized selectively by prazosin, but not by rauwolscine [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;]. In a standardized rat primary observation test, the compound (30 mg/kg, po), caused a strong vigilance increase [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;]. At the same dose, it antagonizes the sedation induced by diethyldithiocarbamate, a dopamine beta-hydroxylase inhibitor and the cognitive impairment induced by the neurotoxin, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;].  Administered to Saimiri monkeys at doses of 0.3, 1 and 3 mg/kg, po,  &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; exhibits central stimulation, at the highest dose tested, comparable to that seen in the rat. At this dose, no hypertension was observed but there was a slight decrease in blood pressure concomitant with a moderate tachypnea [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In dogs, at doses of 0.5, 1 and 3 mg/kg, po and 50, 200 and 800 microg/kg, iv, &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; inhibits the cataplexy which is related to human rapid eye movement sleep disorder [&lt;ulink linkType="reference" linkID="3708"&gt;3708&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="162768"&gt;162768&lt;/ulink&gt;]. When the compound is administered by the iv route, the effect is accompanied by an moderate increase in body temperature. In contrast, guinea pig body temperature is decreased following a dose of &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; at 1 mg/kg, ip. This hypothermia is probably mediated by 5-HT1d receptors [&lt;ulink linkType="reference" linkID="195970"&gt;195970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I &lt;/subtitle&gt;In healthy young volunteers, there were no clinically relevant effects of &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; on blood pressure or heart rate up to a single dose of 24 mg [&lt;ulink linkType="reference" linkID="215843"&gt;215843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; is described as a centrally acting alpha 1 adrenoceptor agonist devoid of any cardiovascular side-effects liability. This interesting profile was first linked to an alpha 1 adrenoceptor subtype selectivity, but recent data demonstrated that the compound is more potent at 5-HT receptors, with a complex profile of agonism and antagonism at various 5-HT receptor subtypes.&lt;/para&gt;&lt;para&gt;From animal experiments in different species, it seems that &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; has potential for the treatment of vigilance deficit such as narcolepsy and hypersomnia. The fact that &lt;ulink linkType="Drug" linkID="3645"&gt;modafinil&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="17744"&gt;Laboratoire L Lafon SA&lt;/ulink&gt;), another drug thought to act also through an alpha 1 adrenoceptor agonism mechanism has been registered in different countries for the treatment of hypersomnia tends to confirm this hypothesis.&lt;/para&gt;&lt;para&gt;Tentatively, the application of &lt;ulink linkType="Drug" linkID="4391"&gt;SDZ-NVI-085&lt;/ulink&gt; in dementias of various origins and depression, was argued on the basis that the loss of noradrenergic neurons in the loecus coeruleus constitutes a prominent histopathological change in senile dementia and severe depression. In addition, classical antidepressants often increase noradrenergic tone through reuptake inhibition but have never been proven useful for treating Alzheimer's disease. Unfortunately, because no additional reports have been published after the preliminary clinical disclosures of 1992, one is led to believe that no straightforward validation of the hypothesis has yet been reached.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="304">Sleep disorder</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="15">Amnesia</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="90">Dementia</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="353">Cognitive disorder</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="304">Sleep disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="353">Cognitive disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="90">Dementia</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="15">Amnesia</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00106"><Name>Alpha 1A adrenoceptor</Name><SwissprotNumbers><Swissprot>O02824</Swissprot><Swissprot>O77621</Swissprot><Swissprot>P18130</Swissprot><Swissprot>P35348</Swissprot><Swissprot>P43140</Swissprot><Swissprot>P97718</Swissprot><Swissprot>Q91175</Swissprot><Swissprot>Q9WU25</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN1CCO[C@H]2[C@H]1Cc3c(ccc(c3C2)SC)OC</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1418286" number="US-04656167" title="Naphthoxazines And Their Use As Psychostimulating And Antidepressant Agents"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>